Conference Track

Timing and Choice of First-Line Antiretroviral Therapy

Source: CCO Independent Conference Coverage of the CCO Independent Conference Coverage of the 2008 ICAAC/IDSA Annual Meeting*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

STARTMRK: Noninferior Efficacy, Better Tolerability With Raltegravir vs Efavirenz in Antiretroviral-Naive Patients Also Receiving Tenofovir/Emtricitabine
NA-ACCORD: Earlier vs Deferred HAART Initiation Associated With Survival Benefit in Observational Study
MERIT: Comparable Virologic Efficacy With Maraviroc vs Efavirenz in Antiretroviral-Naive Patients After Post Hoc Reanalysis Using Enhanced-Sensitivity Phenotypic Tropism Assay for Screening
HEAT Study: Virologic Failure Rates at Week 96 With Abacavir/Lamivudine vs Tenofovir/Emtricitabine
Study AI266073: Virologic Suppression Maintained in Patients Currently on First-Line HAART Switched to Fixed-Dose Efavirenz/Tenofovir/Emtricitabine
ACTG 5095: Subanalysis of Nevirapine Substitution for HIV Patients With Efavirenz-Associated Toxicity
COL100758: Once-Daily Fosamprenavir/Ritonavir 1400/100 mg vs 1400/200 mg Associated With Similar Efficacy, Safety in Treatment-Naive Patients
No Evidence of CD4+ Cell Count Recovery With Addition of Maraviroc to Stable HAART in Pilot Study of Patients With Virologic Suppression and Blunted CD4+ Cell Response
MERIT: Larger Increase in Absolute CD4+ Cell Count, Similar Increase in CD4+ Cell Percentage With Maraviroc vs Efavirenz Treatment in Antiretroviral-Naive Patients
ARIES: Atazanavir/Ritonavir Plus Abacavir/Lamivudine Effective in Treatment-Naive Patients at Week 36
ARTEMIS: Darunavir/Ritonavir Associated With Greater Virologic Efficacy, Better Tolerability vs Lopinavir/Ritonavir in Treatment-Naive Patients at Week 96
CASTLE: Week-96 Efficacy and Safety of Once-Daily Atazanavir/Ritonavir vs Twice-Daily Lopinavir/Ritonavir in Treatment-Naive Patients at Week 96
Abacavir/Lamivudine-Containing Regimens Efficacious and Generally Safe in HIV-Infected Patients With High Baseline HIV-1 RNA
HIV-1 RNA Suppression With Tenofovir/Emtricitabine vs Abacavir/Lamivudine in First-Line Boosted PI-Based HAART in Systematic Review of 12 Studies
Systematic Review Suggests Greater Risk of Virologic Failure in Patients Switched From Suppressive HAART to Boosted PI Monotherapy Than With Continued HAART

Expert Analysis

First-Line Antiretroviral Therapy

Faculty:

Joel E. Gallant, MD, MPH
W. David Hardy, MD
Kathleen E. Squires, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Summarize the results of the phase III study of raltegravir vs efavirenz in treatment-naive patients
Discuss how the reanalysis of MERIT study with the enhanced phenotypic tropism assay affects the overall results of the study
Recall recent results of early vs deferred antiretroviral therapy
Explain how the 96-week results from ARTEMIS and CASTLE compare with the 48-week results of these studies

CREDIT INFORMATION

Release Date: 12/18/08

Expiration Date: 12/17/09

Physicians: maximum of 1.5 AMA PRA Category 1 Credits™

Registered Nurses: 1.6 Nursing contact hours

Pharmacists: 1.6 contact hours (0.16 CEUs)

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.